Research and Clinical Trials

A Randomized, Open Label, Mulitcenter Study to Evaluate the Efficacy and Safety of Decitabine as Epigenetic Priming with Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) subjects
Brief Description  
This phase II study evaluates the safety and effectiveness of the study drug, decitabine, as a pre-treatment before receiving the standard treatment therapy of daunorubicin, cytarabine,and etoposide in children with Acute Myelogenous Leukemia (AML). Patients will be in this study for approximately 60 days and followed for up to 5 years.
Who may be Eligible  
Males and females age 1-16 years inclusive with diagnosis of AML Exclusions include: Prior chemotherapy or radiation therapy for AML, history of chronic myelogenous leukemia (CML), participated in a drug trial in last 4 weeks
IRB Number  
Principal Investigator  
Oesterheld, Javier

For More Information, Contact  Julie  , Chasnis
Phone:  (704) 446-5154  Fax:  (704) 355-1188  
Address:1025 Morehead Medical Drive Suite 600 Charlotte, NC 28204